TABLE 1.
Characteristics of 177 patients with AML
| Total | ND unfit | R/R | ||||
|---|---|---|---|---|---|---|
| n | 177 | Patients | 72 | Patients | 105 | Patients |
| Age (years) | 63 | 46–74 | 73 | 61–78 | 51 | 40–69 |
| Sex | ||||||
| F | 62 | 35.0% | 23 | 31.9% | 39 | 37.1% |
| M | 115 | 65.0% | 49 | 68.1% | 66 | 62.9% |
| Dx | ||||||
| Acute megakaryoblastic leukemia | 1 | 1.0% | 0 | 0.0% | 1 | 1.0% |
| Acute monoblastic/monocytic leukemia | 22 | 12.0% | 5 | 6.9% | 17 | 16.2% |
| Acute myelomonocytic leukemia | 13 | 7.0% | 5 | 6.9% | 8 | 7.6% |
| Acute panmyelosis with myelofibrosis | 1 | 1.0% | 1 | 1.4% | 0 | 0.0% |
| Acute promyelocytic leukemia with PML‐RARA | 1 | 1.0% | 1 | 1.4% | 0 | 0.0% |
| AML (megakaryoblastic) with t(1; 22)(p13.3; q13.3); RBM15‐MKL1 | 3 | 2.0% | 2 | 2.8% | 1 | 1.0% |
| AML with biallelic mutations of CEBPA | 3 | 2.0% | 0 | 0.0% | 3 | 2.9% |
| AML with inv (16)(p13.1q22) or t(16; 16)(p13.1; q22); CBFB‐MYH11 | 7 | 4.0% | 4 | 5.6% | 3 | 2.9% |
| AML with inv (3)(q21.3q26.2)or t(3; 3)(q21.3; q26.2); GATA2, MECOM(EVI1) | 3 | 2.0% | 0 | 0.0% | 3 | 2.9% |
| AML with maturation | 25 | 14.0% | 8 | 11.1% | 17 | 16.2% |
| AML with minimal differentiation | 6 | 3.0% | 3 | 4.2% | 3 | 2.9% |
| AML with mutated NPM1 | 9 | 5.0% | 2 | 2.8% | 7 | 6.7% |
| AML with myelodysplasia‐related changes | 42 | 24.0% | 26 | 36.1% | 16 | 15.2% |
| AML with t(8; 21)(q22; q22.1); RUNX1‐RUNX1T1 | 15 | 8.0% | 5 | 6.9% | 10 | 9.5% |
| AML with t(9; 11)(p21.3; q23.3); MLLT3‐KMT2A | 1 | 1.0% | 0 | 0.0% | 1 | 1.0% |
| AML without maturation | 13 | 7.0% | 4 | 5.6% | 9 | 8.6% |
| Provisional entity: AML with mutated RUNX1 | 1 | 1.0% | 0 | 0.0% | 1 | 1.0% |
| Pure erythroid leukemia | 1 | 1.0% | 0 | 0.0% | 1 | 1.0% |
| Therapy‐related myeloid neoplasms | 10 | 6.0% | 6 | 8.3% | 4 | 3.8% |
| Allo.SCT | ||||||
| N | 108 | 61.0% | 61 | 84.7% | 47 | 44.8% |
| Y | 69 | 39.0% | 11 | 15.3% | 58 | 55.2% |
Abbreviations: Allo.SCT, allogeneic stem cell transplantation; Dx, diagnosis; F, female; M, male; N, no; ND, newly diagnosed; R/R, relapsed/refractory; Y, yes.